Benefits
Cellular rejuvenation and anti-aging
Rējen™ is positioned as a cellular rejuvenation ingredient targeting multiple hallmarks of aging — cellular senescence accumulation, impaired autophagy, mitochondrial dysfunction, and epigenetic drift. As a newly launched ingredient (late 2025), clinical evidence is in early stages with preclinical mechanistic data supporting the rejuvenation concept.
Longevity pathway activation
Based on Compound Solutions' stated positioning, Rējen™ targets longevity signaling pathways associated with healthspan extension — including autophagy induction, SIRT1/AMPK activation, and reduction of pro-aging inflammatory signals. The ingredient fits within the growing category of senolytic and autophagy-enhancing compounds alongside fisetin, urolithin A, and spermidine.
Mechanism of action
Multi-hallmark aging intervention
Rējen™ is designed to address multiple hallmarks of aging simultaneously — the approach supported by longevity research showing that interventions targeting single pathways have modest effects, while multi-target approaches addressing cellular senescence, proteostasis, mitochondrial dysfunction, and epigenetic alterations produce more robust healthspan extension. Specific mechanistic details pending full ingredient disclosure.
Clinical trials
Newly launched ingredient (late 2025). Per Compound Solutions, clinical trials underway; preclinical mechanistic data only currently available.
Rējen™ is a proprietary cellular rejuvenation complex from Compound Solutions. The Rējen™ branded formulation does not have a dedicated PubMed-indexed clinical trial as of May 2026. Component-level evidence depends on the specific actives in the formula (typically including senolytic and NAD+-related compounds).
Caveat: No specific Rējen™ branded clinical trial in PubMed. Manufacturer claims of "cellular rejuvenation" and "healthy aging support" are not backed by a dedicated peer-reviewed trial. The general cellular senescence/senolytic field has substantial PubMed-indexed mechanistic evidence (e.g., Zhu 2019 senolytics review), but those findings do not transfer automatically to this branded blend without independent validation. Evidence-level 1: not yet validated in human clinical trial for the specific Rējen™ formulation. Recommend formulators wait for peer-reviewed publication before relying on branded efficacy claims.